MARCH 27
Days
- :
Hrs
- :
Min
- :
Sec
ePoster Gallery
P108: Perioperative Outcomes and Technical Feasibility of A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in Treatment of Pancreatic Cancer Liver Metastases
Jason Aubrey MD
Corewell Health West - Michigan State University
P110: Postoperative Decision Regret is Higher in Patients with Pancreatic Ductal Adenocarcinoma who are Non-English Primary Speakers or with Poor Health Literacy
Judy Li MD
Icahn School of Medicine at Mount Sinai
P111: Postoperative Pancreatic Fistula after Pancreatoduodenectomy: can radiomics improve clinical risk scores?
Ankur Choubey MD MPH
Memorial Sloan Kettering Cancer Center
P112: Recurrence Timing and Risk Following Curative Resection of Colorectal Liver Metastases: Insights from a Hazard Function Analysis
Diamantis Tsilimigras MD, PhD
The Ohio State University
P113: Redefining Upfront Resectable Pancreatic Ductal Adenocarcinoma:Does Vein Abutment Matter?
Po Hong Tan MBBS
Mayo Clinic
P115: SMAD4 Alterations Are a Predictive Biomarker to Guide First-line Chemotherapy Selection for the Neoadjuvant Treatment of Localized Pancreatic Cancer
Julia Button MD
Duke University Medical Center
P116: SMAD4 Intratumoral Heterogeneity in Pancreatic Cancer and its Biological Implications for Standard Therapeutic Agents
Natalie Williams MD
UTSouthwestern Medical Center
P117: Subasumstat Synergizes with 5-Fluorouracil and Irinotecan to Enhance Cytotoxicity in Pancreatic Cancer In Vivo
Asimina Courelli
University of California, San Diego
P118: Surgical and Oncologic Outcomes of Open vs Laparoscopic vs Robotic Parenchyma-sparing Operations for Pancreatic Neuroendocrine Tumors: A Multi-Institutional Analysis
Marco Ventin
Cedars-Sinai Medical Center
P119: Surgical Management of Ampullary Neuroendocrine Tumors: A 20+ Year Single Institutional Experience
Dylan Soukup MD, MBA
Mayo Clinic
P122: Title: Pancreatic cancer shows clinical signs far earlier than previously suspected
Parnian Naji
University Hospitals Cleveland
P123: Utility of Next Generation Sequencing for Prediction of Prognosis in Transplant Patients with Multinodular HCC
Michael Mallouh
University of Massachusetts Chan Medical School
P124: Variations in Outcomes of Surgical Oncology Fellowship Graduates Performing Hepatopancreatic Surgery in the United States Based on Fellowship Training Program
Diamantis Tsilimigras MD, PhD
The Ohio State University
P125: Circulating Tumor DNA in High-Risk Stage II/III Melanoma: A Feasibility Study
Kristen Rhodin MD, MHS
Duke University
P126: Compliance with Nodal Basin Ultrasound Surveillance after Positive Sentinel Lymph Node Biopsy
Natalie Chakraborty M.D.
University Hospitals Cleveland Medical Center/Case Western Reserve University
P127: Contemporary survivorship care patterns and management of treatment-related toxicities for melanoma patients
Valerie Francescutti MD
McMaster University/Hamilton Health Sciences
P128: Discordant PD-L1 Expression on Primary Tumor versus Circulating Tumor Cells in Cutaneous Melanoma
Jennifer Chen
The University of Texas MD Anderson Cancer Center
P129: Does Therapy Duration Matter for Stage III Melanoma Patients Receiving Adjuvant Immunotherapy?
Natalie Chakraborty M.D.
University Hospitals Cleveland Medical Center/Case Western Reserve University